Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …

It is not known exactly where amyloid-β (Aβ) fibrils begin to accumulate in individuals with
Alzheimer's disease (AD). Recently, we showed that abnormal levels of Aβ42 in …

Pathological perturbations of the brain are rarely confined to a single locus; instead, they
often spread via axonal pathways to influence other regions. Patterns of such disease …

Introduction We performed a systematic review and meta-analysis of the Alzheimer's
disease (AD) literature to examine consistency of functional connectivity alterations in AD …

As the field begins to test the concept of a" preclinical" stage of neurodegenerative disease,
when the pathophysiological process has begun in the brain, but clinical symptoms are not …

Abstract Streptozotocin (STZ), a glucosamine-nitrosourea compound derived from soil
bacteria and originally developed as an anticancer agent, in 1963 has been found to induce …

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued
development and standardization of methodologies for biomarkers and has provided an …

A common finding in human functional brain-imaging studies is that damage to neural
systems paradoxically results in enhanced functional connectivity between network regions …

A major mystery of many types of neurological and psychiatric disorders, such as
Alzheimer's disease (AD), remains the underlying, disease-specific neuronal damage …